DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for intellectual developmental disorder 62 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntellectual developmental disorder 62 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intellectual developmental disorder 62 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
acyl-CoA dehydrogenase very long chain (ACADVL) — ACADVL is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet faddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7S7G · 1.34 Å · ligand FLAVIN-ADENINE DINUCLEOTIDE (FAD). Experimental structure, not a prediction.
What the evidence adds up to
Intellectual developmental disorder 62 is a genetic condition for which no specific treatment exists. A 2018 review states plainly that for intellectual disability generally, "there is no specific treatment." A 2022 review on homoeopathic management acknowledges that intellectual disability disorder affects 6 to 8% of the global population and that about half of those affected are children, but it offers no clinical data, no patient numbers, and no measured outcomes to support its claim that homoeopathic medicine "will remove the disease from the root cause." A 2011 article on Fragile X syndrome, the most common inherited form of intellectual disability, describes the possibility that pharmaceutical therapies might one day treat underlying cognitive deficits, but this remains a future prospect, not a present result.
A 1994 study of 300 children with serious emotional disorders found that their intellectual abilities did not differ strongly from the general population, and that children referred to inpatient versus day treatment had similar intellectual competency. This study does not address intellectual developmental disorder 62 specifically, and its findings are about emotional disorders, not genetic intellectual disability. No abstract reports any drug tested in patients with intellectual developmental disorder 62, nor any clinical trial, response rate, or survival data for this condition.
What is still missing is any clinical trial for intellectual developmental disorder 62, any funding for such a trial, any identified drug candidate tested in humans with this specific mutation, and any patient stratification strategy that might distinguish responders from non-responders. The gap between a general hope that intellectual disability might become treatable and the reality of a named genetic disorder with no tested therapy remains unbridged.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
ACS Chemical Neuroscience · 2011 · 19 citations · open access
Fragile X Syndrome: An Update on Developing Treatment Modalities
AbstractIntellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.
Journal of Clinical Psychology · 1994 · 13 citations
Intellectual competence of children who are beginning inpatient and day psychiatric treatment
AbstractIntellectual abilities of 300 children with serious emotional disorders, referred to either psychiatric day- or inpatient-hospital treatment, were compared. Comparisons also were made to WISC-R standardization data. The findings indicated that children referred to inpatient settings were similar in intellectual competency to children in day treatment. Also, children with serious emotional disorders did not appear to differ strongly in clinically meaningful ways from the WISC-R standardization sample, a finding that replicates results of other investigators. Three distinct, clinically useful profiles emerged from a cluster analysis of the total group that may be practical in planning educational and therapeutic interventions in treatment settings for seriously disturbed children. The profiles underscored the wide range of intellectual abilities represented among these children.
Residência Pediátrica · 2018 · 1 citations · open access
Inetellectual disabilities in children
AbstractMental retardation, more appropriately known as intellectual disability (ID), is a common neurologic condition in childhood and adolescence. The clinical deficits involve cognition and adaptive behavior, and its onset occurs before 18 years of age. There is a number of etiologies, ranging from prenatal, perinatal and postnatal factors to cases of genetic origin. Many genetic syndromes are associated with ID. There is no specific treatment. General care requires the participation of several professionals, while the pediatrician acts as the coordinator of referrals to a range of specialties, according to the needs of the clinical picture.
International Journal of Homoeopathic Sciences · 2022 · 0 citations · open access
An overall review on intellectual disability disorder and its homoeopathic management
AbstractThe Intellectual Disability Disorder is found as a one of the clinical manifestations of the rare disorders which occupies a total prevalence of about 6 to 8% globally. The rare disorder is found to cause many of the chronic disabilities in which the intellectual disability disorder is one of them which has a drastic impact on the individual who is affected and their families and includes the health care system. The onset period of the rare disorder begins from the prenatal period into the late adulthood and it is being assessed that about the half of the individual affected are children [1]. The prime and the only purpose of this study undertaken is to find the effectiveness of the homoeopathic medicine in the treatment of the Intellectual Disability Disorder and also to alter their intellectual and the adaptive functions of the affected individual. The homoeopathic medicine will remove the disease from the root cause.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
